Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Prevention, Diagnosis, and Treatment of HPV Associated Cancers
share announcement

Personalized Prevention, Diagnosis, and Treatment of HPV Associated Cancers

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Epidemiology".

Deadline for manuscript submissions: closed (25 September 2023) | Viewed by 7971

Special Issue Editor

Dr. Pluvio J. Coronado

E-Mail Website
Guest Editor
1. Department of Obstetrics and Gynecology, Complutense University of Madrid, Madrid, Spain
2. Head of Gynecology Oncology Unit, Hospital Clinico San Carlos, Madrid, Spain
Interests: cervical cancer; endometrial cancer; ovarian cancer

Special Issue Information

Dear Colleagues,

The human papillomavirus (HPV) has not only been associated with cervical cancer but with other tumors in men, as well as in women. HPV-related premalignant and malignant lesions have been demonstrated in the oropharyngeal, vagina, vulva, anus, and penis. The burden of disease HPV-related is wide and implies an elevated sanitary cost. Nowadays, we count the vaccines against HPV as primary prevention, but HPV determination as secondary prevention is only demonstrated in cervical cancer screening. In addition, there is no HPV-directed treatment, we can only treat the associated lesion, and the immune system is the unique way to clear the infection. HPV persistence and latency and how the biological behavior in each site of infection are today non-resolved issues. New research related to HPV prevention, diagnosis, management, and treatment is necessary to improve the knowledge about HPV infection and its consequences in women and men, especially in special population as immunosuppressed.

Dr. Pluvio J. Coronado
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • human papillomavirus
  • HPV
  • prevention
  • treatment
  • screening
  • persistence
  • latency
  • inferior genital tract
  • oropharynge
  • anal

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

11 pages, 556 KiB  
Article
Prevalence of Anal High-Risk Human Papilloma Virus Infection and Abnormal Anal Cytology among Women Living with HIV
by Leticia Muñoz-Hernando, Reyes Oliver-Pérez, Victoria Bravo-Violeta, Alejandro Olloqui, Belen Parte-Izquierdo, Cristina Almansa-González, Rocio Bermejo-Martinez, Ana Belen Bolivar-De Miguel, Alvaro Diez, Jose Miguel Seoane-Ruiz, Lucia Parrilla-Rubio and Alvaro Tejerizo-García
J. Pers. Med. 2022, 12(11), 1778; https://doi.org/10.3390/jpm12111778 - 28 Oct 2022
Cited by 1 | Viewed by 1300
Abstract
Background: Women living with human immunodeficiency virus (HIV), WLWHs, are at high risk of developing anal cancer associated with high-risk human papilloma virus infection (HR-HPV). We analyzed the prevalence of anal HR-HPV infection and abnormal anal cytology in a cohort of WLWHs and [...] Read more.
Background: Women living with human immunodeficiency virus (HIV), WLWHs, are at high risk of developing anal cancer associated with high-risk human papilloma virus infection (HR-HPV). We analyzed the prevalence of anal HR-HPV infection and abnormal anal cytology in a cohort of WLWHs and assessed the risk factors for anal HR-HPV infection. Methods: We present a single-center, observational cross-sectional study. WLWHs who underwent anal cytology and anal human papilloma virus (HPV) testing were selected. High-resolution anoscopy was performed in cases of abnormal anal cytology. All suspicious lesions were biopsied. A univariate and multivariate logistic regression model was used to analyze risk factors for abnormal anal screening. The results are presented as odds ratios (ORs) and 95% confidence intervals (CIs). Results: In total, 400 WLWHs were studied. Of them, 334 met the eligibility criteria and were enrolled in the study. Abnormal anal cytology was detected in 39.5% of patients, and anal HR-HPV in 40.1%, with HPV 16 in 33 (26.6%) of them. Concomitant HR-HPV cervical infection was the only independent risk factor for HR-HPV anal infection (OR 1.67 95% CI, p < 0.001). Conclusions: WLWHs have a high prevalence of HR-HPV anal infection and anal cytologic abnormalities. HR-HPV cervical infection is the main predictor of HR-HPV anal infection. Full article
(This article belongs to the Special Issue Personalized Prevention, Diagnosis, and Treatment of HPV Associated Cancers)
►▼ Show Figures

Figure 1

7 pages, 1050 KiB  
Article
Efficacy of a Coriolusversicolor-Based Vaginal Gel in Human Papillomavirus-Positive Women Older Than 40 Years: A Sub-Analysis of PALOMA Study
by Santiago Palacios Gil-Antuñano, Luis Serrano Cogollor, Andrés C. López Díaz, Silvia P. González Rodríguez, Damián Dexeus Carter, Cristina Centeno Mediavilla, Pluvio Coronado Martín, Jesús de la Fuente Valero, José A. López Fernández, Cristina Vanrell Barbat and Javier Cortés Bordoy
J. Pers. Med. 2022, 12(10), 1559; https://doi.org/10.3390/jpm12101559 - 22 Sep 2022
Cited by 3 | Viewed by 2198
Abstract
In the PALOMA trial, Papilocare® demonstrated efficacy in repairing low-grade cervical lesions related to human papillomavirus (HPV). This sub-analysis aimed to evaluate its efficacy in repairing these cervical lesions and clearing HPV in women aged older than 40 years. This was a [...] Read more.
In the PALOMA trial, Papilocare® demonstrated efficacy in repairing low-grade cervical lesions related to human papillomavirus (HPV). This sub-analysis aimed to evaluate its efficacy in repairing these cervical lesions and clearing HPV in women aged older than 40 years. This was a multicenter, randomized, open-label, parallel-group, controlled clinical trial. Patients with low-degree HPV-dependent cervical lesions receiving 6-month treatment with the vaginal gel were compared to those with a watchful waiting approach. Among the 41 women analyzed (aged 47.7 years), 31 presented high-risk (HR) oncogenic HPV subtypes, and 14 had 16-18-31 HPV genotypes. After 6 months, normalized cytology and concordant colposcopy were achieved by a greater percentage of treated women. The difference was significant in the total population (92.3% vs. 50.0%, p = 0.007), and HR-HPV subpopulation (90.5% vs. 33.3%, p = 0.003). In the HR HPVs-16-18-31 subpopulation, the values were 75.0% and 40.0% (p = 0.293). In the total population, 61.5% of treated patients obtained HPV clearance, compared to 50.0% in the control group. Regarding the HR-HPV subpopulation, these values were 66.7% and 44.4%, respectively. Papilocare® demonstrated significant efficacy in repairing low-degree HPV-related cervical lesions and a positive trend to clear HPV in women older than 40 years old in comparison to the watchful waiting approach. Full article
(This article belongs to the Special Issue Personalized Prevention, Diagnosis, and Treatment of HPV Associated Cancers)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research, Other

13 pages, 1889 KiB  
Review
Glycyrrhizinic Acid as an Antiviral and Anticancer Agent in the Treatment of Human Papillomavirus
by Victoria Bravo, María Serrano, Alfonso Duque, Juan Ferragud and Pluvio J. Coronado
J. Pers. Med. 2023, 13(12), 1639; https://doi.org/10.3390/jpm13121639 - 24 Nov 2023
Viewed by 2035
Abstract
Human papillomavirus (HPV), like any other virus, needs to penetrate the host cell and make use of its machinery to replicate. From there, HPV infection can be asymptomatic or lead to benign and premalignant lesions or even different types of cancer. HPV oncogenesis [...] Read more.
Human papillomavirus (HPV), like any other virus, needs to penetrate the host cell and make use of its machinery to replicate. From there, HPV infection can be asymptomatic or lead to benign and premalignant lesions or even different types of cancer. HPV oncogenesis is due to the ability of the viral oncoproteins E6 and E7 to alter the control mechanisms for the growth and proliferation of host cell. Therefore, the use of agents with the ability to control these processes is essential in the search for effective treatments against HPV infections. Glycyrrhizinic acid (Gly), the active ingredient in liquorice, has been shown in numerous preclinical studies to have an antiviral and anticancer activity, reducing the expression of E6 and E7 and inducing apoptosis in cervical cancer cells. In addition, it also has antioxidant, anti-inflammatory, immunomodulatory or re-epithelializing properties that can be useful in HPV infections. This review includes the different antiviral and anticancer mechanisms described for Gly, as well as the clinical studies carried out that position it as a potential therapeutic strategy against HPV both through its topical application and by oral administration. Full article
(This article belongs to the Special Issue Personalized Prevention, Diagnosis, and Treatment of HPV Associated Cancers)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research, Review

8 pages, 1541 KiB  
Case Report
The Association of Four Natural Molecules—EGCG, Folic Acid, Vitamin B12, and HA—To Counteract HPV Cervical Lesions: A Case Report
by Giovanni Grandi, Laura Botticelli, Pietro Di Fraia, Carla Babalini, Meris Masini and Vittorio Unfer
J. Pers. Med. 2023, 13(3), 567; https://doi.org/10.3390/jpm13030567 - 22 Mar 2023
Viewed by 1647
Abstract
Precancerous lesions of the uterine cervix, due to HPV infections, are still today a great medical challenge. This clinical case highlighted the effectiveness of epigallocatechin gallate (EGCG), vitamin B12, folic acid, and hyaluronic acid (HA) in counteracting HPV lesions in a 39-year-old patient [...] Read more.
Precancerous lesions of the uterine cervix, due to HPV infections, are still today a great medical challenge. This clinical case highlighted the effectiveness of epigallocatechin gallate (EGCG), vitamin B12, folic acid, and hyaluronic acid (HA) in counteracting HPV lesions in a 39-year-old patient with a long history of viral persistence, cervical lesions of various degree, and several unsuccessful surgical approaches. After eight weeks of treatment, both the histological and cytological analyses revealed only a chronic cervicitis without any malignant lesions or cellular dysplasia, thus reducing the urgency of an invasive surgery, a total hysterectomy. Full article
(This article belongs to the Special Issue Personalized Prevention, Diagnosis, and Treatment of HPV Associated Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop